FTRE - Financial Snapshot

Non-Cash Charge Rank: 346

📈 Metrics for FTRE

Price	$10.65
netCurrentAssetsPerShare	$-14.16 netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
netTangibleAssetsPerShare	$0 netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
maxEarningPowerPerShare	$-30.16 maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
adjustedEarningPower	$-34.49 adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
nonCashChargeToMKTCAP	2.68% nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
cashValuePerShare	$0 cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding

Data as of: Price 09-18-25 16:00 ET, Balance Sheet 2025-06-30, Income Statement 2025-06-30

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.